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Prostate Cancer Can Be Detected Even in Patients with Decreased 
PSA Less than 2.5 ng/ml after Treatment of Chronic Prostatitis 
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Seung Il Jung, Taek Won Kang, Dong Deuk Kwon, Kwangsung Park, Soo Bang Ryu
Department of Urology, Chonnam National University Medical School, Gwangju, Korea
Purpose: We evaluated men with documented chronic prostatitis and elevated serum 
prostate-specific antigen (PSA) to determine whether treatment with antibiotics and 
anti-inflammatory drugs can lower serum PSA and the cancer detection rate in patients 
with post-treatment PSA ＜4 ng/ml. 
Materials and Methods: Eighty-six men who presented with serum PSA greater than 
4 ng/ml and who were subsequently diagnosed with chronic prostatitis with greater 
than 10 white blood cells per high power field in expressed prostatic excretions were 
included in this prospective study. Patients meeting these criteria underwent treat-
ment with a 4-week course of antibiotics and nonsteroidal anti-inflammatory agents. 
Follow-up PSA and transrectal ultrasonography-guided prostate biopsy were per-
formed within 2 months of treatment for all patients. 
Results: Mean patient age was 56.2 years (range, 37-72 years). Mean PSA (ng/ml) de-
creased by 33.8%, from 8.12 (range, 4.02-24.8) to 5.37 (range, 1.35-12.94), after treat-
ment (p=0.001). Pathological studies revealed prostate cancer in 18 cases (20.9%), 
chronic inflammation in 64 (74.4%), and benign prostatic hypertrophy in 4 (4.7%). The 
prostate cancer detection rate according to the follow-up PSA level, below 2.5, from 2.5 
to 4.0, and above 4.0, was 13.3% (2/15), 13.6% (3/22), and 26.5% (13/49), respectively. 
Conclusions: When chronic prostatitis with elevated PSA is identified, antibiotic and 
anti-inflammatory treatment can lower these PSA levels. However, the possibility of 
prostate cancer remains in patients whose PSA level decreases to less than 4 ng/ml, 
even in those with a PSA level less than 2.5 ng/ml. 
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INTRODUCTION
Prostate-specific antigen (PSA) is the most commonly used 
marker for screening of prostate cancer, and men with ele-
vated serum PSA of greater than 4 ng/ml are considered to 
be at higher risk for prostate cancer [1]. These patients are 
usually referred to undergo a prostate biopsy [2,3]. Howev-
er, it is known that increased PSA is not necessarily due 
to prostate cancer, but can also be associated with con-
ditions other than cancerous lesions, such as prostate in-
flammation [4,5]. The recommended cutoff value of PSA for 
needle biopsy of the prostate has recently been lowered to 
2.5 ng/ml [2]. In support of the possible incidence of prostate 
cancer in men with a PSA level lower than 4 ng/ml, Gilbert 
et al reported a similar prostate cancer detection rate be-
tween patients with a PSA level of 2.5 to 4 ng/ml (27.48%) 
and patients with a PSA level between 4 and 10 ng/ml 
(30.8%) [3]. 
Until now, many studies have investigated the correla-
tion of serum PSA and prostate inflammation to provide 
answers to the question of whether unnecessary biopsies 
could be avoided by treatment of chronic prostatitis and 
lowering of PSA [6,7]. These studies suggested that identi-
fication and treatment of prostatitis can decrease PSA and Korean J Urol 2011;52:457-460
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TABLE 1. Patients characteristics and comorbidity 
Patients characteristics Mean (%)
Age (yr)
Pre-treatment PSA (ng/ml)
Post-treatment PSA (ng/ml)
Relative changes (%)
a
Post-treatment PSA (ng/ml) range
    PSA＜2.5
    2.5≤PSA＜4.0
    PSA≥4.0 
56.2±12.3 (37-72)
8.12±3.2 (4.62-24.8)
  5.37±3.6 (1.35-12.94)
   33.8
15
22
49
PSA: prostate-specific antigen, 
a: p=0.001
TABLE 2. The results of TRUS biopsy and prostate cancer 
detection rate in patients with various post-treatment PSA
Biopsy results  No. of events (%)
Prostate cancer
BPH with prostatitis 
BPH alone
18 (20.9%)
64 (74.4%)
4 (4.7%)
PSA range (ng/ml)   Detected prostate cancer (%)
PSA＜2.5 (15)
2.5≤PSA＜4.0 (22)
PSA ≥4.0 (49)
  2 (13.3)
  3 (13.6)
13 (26.5)
Total 18  (20.9)
TRUS: transrectal ultrasonography, PSA: prostate-specific anti-
gen, BPH: benign prostatic hyperplasia
thus decrease the number of men with an indication for 
prostate biopsy for cancer evaluation. However, the main 
drawback of the reported studies is that pathologic results 
are not available for patients with a post-treatment PSA 
level ＜4 ng/ml because they did not undergo a prostate 
biopsy. We evaluated men with documented chronic pros-
tatitis and elevated serum PSA to determine whether 
treatment with antibiotics and anti-inflammatory drugs 
can lower serum PSA. In addition, we performed prostate 
biopsy after treatment in all cases and examined the cancer 
detection rate in patients whose PSA decreased to less than 
4 ng/ml after treatment with antibiotics and anti-in-
flammatory agents to determine the real number of pa-
tients requiring prostate biopsy and the necessity of biopsy.
MATERIALS AND METHODS
Between January 2006 and December 2008, a total of 86 
consecutive patients between the ages of 50 and 65 years 
who presented with serum PSA (ng/ml) above 4 with a nor-
mal digital rectal exam (DRE) result and who were sub-
sequently diagnosed with chronic prostatitis were enrolled 
in this prospective, observational study. We identified 
chronic prostatitis as greater than 10 white blood cells per 
high power field in expressed prostatic excretions obtained 
from prostatic massage. All DREs were performed by the 
special medical doctor in urology. The presence of a pal-
pable nodule, enduration, fluctuation, or fixed prostate 
was regarded as an abnormal DRE result. Patients with 
known prostate cancer or recent transurethral resection of 
the prostate, usage of prior 5-alpha reductase inhibitors, 
transurethral catheter insertion, or urinary retention in 
the past 6 weeks were excluded. The subjects provided in-
formed consent for prostate biopsy and for participation in 
this study.
Patients meeting these criteria received treatment with 
a 4-week course of combination pharmacological therapy 
with antibiotics (ciprofloxacin, 500 mg/day) and a non-
steroidal anti-inflammatory agent (zaltoprofen 80 mg, 
three times a day). Follow-up PSA and transrectal ultra-
sonography-guided prostate biopsy were performed within 
2 months after treatment for all patients. Transrectal ul-
trasound-guided 10-core prostate biopsies were obtained 
from patients by the same urologist with use of a 7.5 MHz 
probe (Viking 2400, BK Medical, Denmark). An automated 
biopsy gun and an 18-gauge needle were used. Prophylactic 
antibiotics were administered to all patients with cipro-
floxacin 500 mg twice a day for 5 days starting the day be-
fore the biopsy. Pathologic specimens were evaluated by 
the pathologist with regard to the presence of carcinoma 
of the prostate.  
RESULTS
The mean patient age was 56.2 years. The basal PSA level 
(ng/ml) was 8.12 (range, 4.62-24.8). After 4 weeks of anti-
biotics and nonsteroidal anti-inflammatory agents, mean 
PSA showed a significant decrease to 5.37 (range, 1.35- 
12.94) (p=0.001) (Table 1). The relative percentage change 
in PSA before and after treatment was estimated at 33.8%. 
PSA after 4 weeks of treatment was determined as below 
2.5 in 15 cases, from 2.5 to 4.0 in 22 cases, and above 4.0 
in 49 cases (Table 1). From the transrectal prostate biopsy 
after treatment, prostate cancer was detected in 18 cases 
(20.9%), followed by chronic inflammation in 64 cases 
(74.4%), and benign prostatic hypertrophy in 4 cases (4.7%) 
(Table 2). We found that PSA in 37 of 86 (43%) of the patients 
with elevated PSA above 4 ng/ml decreased to a normal 
range of below 4 ng/ml after 4 weeks of treatment. Among 
these cases, PSA was determined as below 2.5 in 15 cases 
(17.4%) after treatment. The estimated prostate cancer de-
tection rate according to the follow-up PSA range, below 
2.5, from 2.5 to 4.0, and above 4.0, was 13.3% (2/15), 13.6% 
(3/22), and 26.5% (13/49), respectively (Table 2). 
DISCUSSION
In the present study, we demonstrated that the mean PSA 
was significantly decreased after 4 weeks of treatment with 
antibiotics and nonsteroidal anti-inflammatory agents, 
showing an estimated relative percentage change in PSA 
from before to after treatment of 33.8%. We found that PSA 
in 37 of 86 (43%) of the patients with elevated PSA de-Korean J Urol 2011;52:457-460
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creased to a normal range (below 4 ng/ml) after 4 weeks of 
treatment. Among those patients, PSA was determined to 
be below 2.5 in 15 cases (17.4%) after treatment. Further-
more, the prostate cancer detection rate according to the 
follow-up PSA level, below 2.5, from 2.5 to 4.0, and above 
4.0, was 13.3%, 13.6%, and 26.5%, respectively. Overall, a 
relatively high rate of cancer of 13.5% (5/37) was detected 
in those with a decreased to normal value of PSA (below 4 
ng/ml) after treatment. Our results suggest a strong link 
between prostate inflammation and neoplastic trans-
formation, although others refute this connection [8-11]. Of 
the 5 patients, 1 patient (20%) had a Gleason score of 6 or 
less (PSA 2.5-4.0), 2 patients (40%) had a score of 7, and 2 
patients (20%) had a score of 8 or above. The most important 
point of our study results is that clinically significant pros-
tate cancer can be detected even in cases in which the PSA 
level is decreased to less than 2.5 ng/ml after treatment 
with antibiotics and nonsteroidal anti-inflammatory 
agents. These results suggest that a decreased PSA value 
after antibiotic treatment does not implicate the absence 
of prostate cancer and waive the necessity for biopsy. 
Increased PSA can be associated with conditions other 
than cancerous lesions, such as benign prostatic hyper-
plasia, prostate inflammation, and interventions such as 
prostate massage, prostate biopsy, and transurethral 
resections. An elevated PSA level is reported to be related 
to prostatitis [4,6,7,12], and prostate inflammation is 
known to be a main reason for compromise of the specificity 
of PSA [13]. Many studies have shown that treatment of 
chronic prostatitis can decrease the PSA level, which sug-
gests that the use of antimicrobial or nonsteroidal anti-in-
flammatory agents may reduce the number of men who re-
quire prostate biopsy [6,7]. These reports have raised the 
question of how to manage men with elevated PSA and 
chronic prostatitis. Potts investigated 122 medical records 
of patients with elevated PSA and found 41% to have in-
flammatory signs in expressed prostatic secretions or 
post-prostatic massage urine [6]. The author reported that 
the PSA value decreased to the normal value in 43% of pa-
tients with laboratory signs of prostatitis after antibiotic 
treatment. However, prostate biopsy was conducted only 
in patients with persistently elevated PSA after antibiotic 
treatment, not in those with normalized PSA. Bozeman et 
al performed a retrospective evaluation of the medical re-
cords of 95 patients with an elevated PSA level and in-
flammation in expressed prostatic secretions who received 
treatment with antibiotics and anti-inflammatory drugs 
for a period of 4 weeks [7]. They reported that the PSA value 
decreased by 36% from the baseline after treatment with 
antibiotics and nonsteroidal anti-inflammatory agents in 
men with chronic prostatitis and that 44 (46.3%) of the pa-
tients had post-treatment PSA values of lower than 4 
ng/ml, hence avoiding biopsy, whereas the remaining 51 
(53.7%) underwent biopsy, revealing the presence of cancer 
in 13 (25.5%). They conclusively suggested that their pos-
itive biopsy rate improved from 13.7% to 25.5% with initial 
treatment of chronic prostatitis. The major limitations of 
the two studies described above are that biopsy was not per-
formed in all cases but was undertaken only in patients who 
had had post-treatment PSA levels that remained persis-
tently elevated above the normal value. Lowering the PSA 
level may not completely preclude the performance of a 
prostate biopsy to rule out the presence of prostate cancer. 
The recommended cutoff value of PSA for needle biopsy 
of the prostate was recently lowered to 2.5 ng/ml [2]. In sup-
port of the possible incidence of prostate cancer with a PSA 
level lower than 4 ng/ml, Gilbert et al reported a similar 
prostate cancer detection rate between patients with a PSA 
level of 2.5 to 4 ng/ml (27.48%) and patients with a PSA level 
between 4 and 10 ng/ml (30.8%) [3]. Also recently, Lee et 
al reported that the prostate cancer detection rate was 9.6% 
in men with a PSA level lower than 4 ng/ml, which is lower 
than the 12.4% previously reported by Lee at al in Koreans 
[14,15]. Those authors suggested that a prostate cancer 
screening test is required with a PSA level of 2.5 to 2.9 ng/ml 
if the patients have conditions such as older age, smaller 
prostate, and higher PSAD. Most of these studies lacked 
histopathological sampling of the prostate in patients with 
normalized PSA levels after treatment [7]. Baltaci et al re-
ported that although antibiotic therapy will decrease total 
serum PSA, it will not decrease the risk of prostate cancer, 
even though the PSA level decreases to less than 4 g/ml [16]. 
After performance of prostate biopsy in all patients, they 
found prostate cancer in 23 of 100 men (23%) presenting 
with a PSA value in the range of 4-10 ng/ml. Most im-
portantly, they determined that 17 of 100 men had a PSA 
value of less than 4 ng/ml after antibiotic treatment and 
that prostate cancer was detected as many as 5 of these 17 
(29.4%) men. Thompson et al have already reported that 
as many as 26.9% of men with a PSA level between 2.5 and 
4 ng/ml have biopsy-detectable prostate cancer [17]. 
Stopiglia et al conducted the first prospective, double- 
blind, randomized study comparing the behavior of PSA af-
ter treatment with antibiotics vs placebo in patients with 
type IV prostatitis and elevated PSA [18]. They included 
patients presenting with a PSA as low as 2.5 ng/ml in the 
prostate biopsy procedure and unexpectedly found a rela-
tively high rate of cancer in those with a PSA even lower 
than 2.5 ng/ml during follow-up with placebo (30%) or anti-
biotics (55.5%). They conclusively stated that in patients 
with normalized levels of PSA (below 2.5 ng/ml), the ab-
sence of prostate cancer is not indicated, and should not be 
valued in the decision to perform prostate biopsy or not.
This report calls attention to the not infrequent presence 
of prostate cancer, even in patients with normal PSA, after 
antibiotic treatment in patients with elevated PSA and 
chronic prostatitis. This clinical event should be consid-
ered in counseling on the necessity of prostate biopsy in-
dependent of the post-treatment PSA level in patients with 
elevated PSA and chronic prostatitis, even with a PSA de-
crease to ＜2.5 ng/ml. 
This study had some limitations. The number of patients 
included in the study was very small. In addition, our study 
did not have a placebo control group. Thus, considering the Korean J Urol 2011;52:457-460
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low number of cases of chronic prostatitis with elevated 
PSA in the clinical setting, a multicenter, double-blind, pla-
cebo-controlled trial would be ideal for further determi-
nation of the exact relationship between elevated PSA and 
prostate inflammation. Many important variables in this 
analysis, such as the severity of benign prostatic hyper-
plasia and prostate volume, were not considered. Despite 
these limitations, we believe that our study provides some 
valuable clues for guidance in the decision on whether to 
perform prostate biopsy in these patients. 
CONCLUSIONS
The results of this study demonstrate that chronic prostati-
tis can cause elevation of serum PSA levels. When chronic 
prostatitis with elevated PSA is identified, treatment with 
antibiotics and anti-inflammatory agents can lower these 
PSA levels. However, the possibility of clinically sig-
nificant prostate cancer remains in patients with a de-
creased PSA level of less than 4 ng/ml, even in those whose 
PSA decreases to less than 2.5 ng/ml. Therefore, active 
screening tests for prostate cancer should be conducted in 
patients within the normal range of PSA after treatment 
of chronic prostatitis.
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